Torre D, Speranza F, Pugliese A, Tambini R
Division of Infectious Diseases, Regional Hospital and E. and S. Macchi Foundation, Varese, Italy.
Infect Immun. 1990 Dec;58(12):4153-5. doi: 10.1128/iai.58.12.4153-4155.1990.
In this study we report that treatment with recombinant human interleukin-1 beta (rIL-1 beta) (10 U per mouse, intraperitoneally) significantly increased the number of inflammatory macrophages in the peritoneal cavity of mice treated with pertussis toxin (PT) (1 micrograms per mouse, intravenously). The administration of rIL-1 beta in a single intraperitoneal dose (10 U per mouse) 1 or 2 days before challenge with PT did not prevent the decrease in the number of inflammatory macrophages in the peritoneal cavity of mice. On the other hand, the simultaneous administration of rIL-1 beta and PT, as well as the administration of rIL-1 beta 24 h after injection of PT, significantly counteracted the inhibitory effect of PT on inflammatory peritoneal macrophages.
在本研究中,我们报告用重组人白细胞介素-1β(rIL-1β)(每只小鼠10单位,腹腔注射)处理显著增加了用百日咳毒素(PT)(每只小鼠1微克,静脉注射)处理的小鼠腹腔内炎性巨噬细胞的数量。在PT攻击前1天或2天以单次腹腔剂量(每只小鼠10单位)给予rIL-1β并不能防止小鼠腹腔内炎性巨噬细胞数量的减少。另一方面,rIL-1β与PT同时给药,以及在注射PT后24小时给予rIL-1β,可显著抵消PT对炎性腹腔巨噬细胞的抑制作用。